What is the role of brigatinib (Alunbrig) in the treatment of non–small cell lung cancer (NSCLC)?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

Brigatinib (Alunbrig) was approved in April 2017 for ALK-positive metastatic NSCLC in patients who have progressed on or are intolerant to crizotinib. Approval was based on the noncomparative, open-label, multicenter ALTA clinical trial. After a median follow-up of 8 months, median duration of response was 13.8 months in patients randomized to receive brigatinib at oral doses of either 90 mg once daily (n = 112) or 180 mg once daily following a 7-day lead-in at 90 mg once daily (n = 110). [182]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!